[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[Eli](/topic/eli)

### Sentiment: XX%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:eli/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/eli/time-series/sentiment.tsv)  
**Current Value**: XX%  
**Daily Average**: XX%  
**1 Week**: XX% -XX%  
**1 Month**: XX% +2%  
**6 Months**: XX% -X%  
**1 Year**: XX% +8%  
**1-Year High**: XX% on 2024-11-12  
**1-Year Low**: XX% on 2025-06-05  

**Most Supportive Themes**
- **Weight Loss Drug Success:** (35%) Eli Lilly's advancements in weight loss treatments, particularly Mounjaro and its oral pill, are generating significant interest.
- **Positive News and Recommendations:** (20%) Positive news and recommendations from financial analysts and media outlets are supporting Eli Lilly.
- **FDA Approval and Market Potential:** (15%) The potential for FDA approval of new drugs and the overall market potential for Eli Lilly's products are viewed positively.
  
**Most Critical Themes**
- **Competition and Market Challenges:** (10%)  Increased competition from Novo Nordisk and other market challenges are being discussed.
- **Legal and Regulatory Issues:** (10%)  Legal challenges and regulatory scrutiny, particularly related to compounded drugs, are creating some uncertainty.
- **Negative Sentiment and Criticism:** (5%)  Some posts express negative sentiment or criticism regarding the company or its products.
  
Network engagement breakdown:  
| Network | Positive   | %   | Neutral    | %   | Negative  | %   |
| ------- | --------   | -   | -------    | -   | --------  | -   |
| X       | XXXXXXXXX  | X%  | XXXXXXXXX  | X%  | XXXXXXXXX | X%  |
| TikTok  | XXXXXXXXX  | X%  | XXXXXXXXXX | XX% | XXXXXXXXX | X%  |
| YouTube | XXXXXXXXX  | XX% | XXXXXXXXX  | XX% | XXXXXXXXX | X%  |
| Reddit  | XXXXX      | X%  | XXXXX      | X%  | XXX       | X%  |
| News    | XXXXXX     | X%  | XXXXX      | X%  | XXX       | X%  |
|         |            |     |            |     |           |     |
| Total   | XXXXXXXXXX | XX% | XXXXXXXXXX | XX% | XXXXXXXXX | XX% |